Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Effect of antiepileptic drugs on various lipid fractions and certain liver enzymes in epileptic patients of Punjab origin

View through CrossRef
Introduction and Aim: Epilepsy requires lifelong therapy with antiepileptic drugs (AEDs) &having medical and psychological consequence. Present study was conducted to observe the effect of different AEDs on lipid profile and certain liver enzymes on epileptic patients. Material and Methods: 50 epileptic patients receiving AEDs for minimum 1 year were recruited as study group and 50 healthy subjects considered as control group. These subjects were recruited from general community of Punjab. Fasting blood samples were drawn from patients and healthy subjects for the evaluation of total cholesterol, triglycerides, LDL-cholesterol, VLDL-cholesterol, HDL-cholesterol, AST, ALT & ALP. Results: Significant increase in total cholesterol, triglycerides, LDL-cholesterol, VLDL- cholesterol was observed in epileptic patients while no significant change was recorded in HDL- cholesterol. Maximum increase in total cholesterol, TGs, LDL-cholesterol, VLDL- cholesterol levels was observed in phenytoin treated patients with reference tovalproic acid, carbamazepine, levetiracetam treated patients. Levels of AST, ALT and ALP were significantly increased in epileptic patients. Maximum increase in AST & ALT was observed in levetiracetam treated epileptic patients and maximum rise in ALP levels was found in carbamazepine treated patients with reference to other AEDs treated patients. Conclusion: Aforementioned observations suggested that epileptic patients treated with phenytoin, valproic acid, carbamazepine & levetiracetam for long time could cause dyslipidemia, might be responsible for various CHD’s and hepatotoxicity in epileptic patients. Routine screening of lipid profile and hepatic enzymes during chronic use of AEDs is recommended.  
Indian Association of Biomedical Scientists
Title: Effect of antiepileptic drugs on various lipid fractions and certain liver enzymes in epileptic patients of Punjab origin
Description:
Introduction and Aim: Epilepsy requires lifelong therapy with antiepileptic drugs (AEDs) &having medical and psychological consequence.
Present study was conducted to observe the effect of different AEDs on lipid profile and certain liver enzymes on epileptic patients.
Material and Methods: 50 epileptic patients receiving AEDs for minimum 1 year were recruited as study group and 50 healthy subjects considered as control group.
These subjects were recruited from general community of Punjab.
Fasting blood samples were drawn from patients and healthy subjects for the evaluation of total cholesterol, triglycerides, LDL-cholesterol, VLDL-cholesterol, HDL-cholesterol, AST, ALT & ALP.
Results: Significant increase in total cholesterol, triglycerides, LDL-cholesterol, VLDL- cholesterol was observed in epileptic patients while no significant change was recorded in HDL- cholesterol.
Maximum increase in total cholesterol, TGs, LDL-cholesterol, VLDL- cholesterol levels was observed in phenytoin treated patients with reference tovalproic acid, carbamazepine, levetiracetam treated patients.
Levels of AST, ALT and ALP were significantly increased in epileptic patients.
Maximum increase in AST & ALT was observed in levetiracetam treated epileptic patients and maximum rise in ALP levels was found in carbamazepine treated patients with reference to other AEDs treated patients.
Conclusion: Aforementioned observations suggested that epileptic patients treated with phenytoin, valproic acid, carbamazepine & levetiracetam for long time could cause dyslipidemia, might be responsible for various CHD’s and hepatotoxicity in epileptic patients.
Routine screening of lipid profile and hepatic enzymes during chronic use of AEDs is recommended.
 .

Related Results

[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct Introduction Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Dual role of Spreading Depolarization in the epileptic focus
Dual role of Spreading Depolarization in the epileptic focus
Abstract Spreading Depolarizations (SDs) are often associated with epileptic discharges. While SDs are traditionally thought contributing to the postictal depressio...
Effect of anti-epileptic drugs on serum lipids in epileptic patients- A case-control study
Effect of anti-epileptic drugs on serum lipids in epileptic patients- A case-control study
Epilepsy is a chronic illness, thus antiepileptic drugs are often used extensively. However, this treatment may be linked to metabolic abnormalities in different body systems, incl...
Characteristics of malignant brain tumor‐associated epileptic spasms
Characteristics of malignant brain tumor‐associated epileptic spasms
AbstractAlthough epilepsy is the most common comorbidity of brain tumors, epileptic spasms rarely occur. Brain tumors associated with epileptic spasms are mostly low‐grade gliomas....
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top